Katie D. Lewis

Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers<i>In Vitro</i>and in the MPTP-Lesioned Primate:<i>R</i>-MDMA Reduces Severity of Dyskinesia, Whereas<i>S</i>-MDMA Extends Duration of ON-Time

Philippe Huot, Tom H. Johnston, Katie D. Lewis et al. · Journal of Neuroscience · 2011 · 83 citations · Full text

UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset

Philippe Huot, Tom H. Johnston, Katie D. Lewis et al. · Neuropharmacology · 2014 · 43 citations

L-dopa Anti-parkinsonian Action, Mixed Dopamine, Serotonin Re-uptake Inhibitor +10

Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine (‘ecstasy’) through iterative chemical redesign: mechanisms and pathways to cell death

Agata M. Wasik, Michael Gandy, Matthew J. McIldowie et al. · Investigational New Drugs · 2011 · 26 citations · Full text

Lymphoid Neoplasia, Anti-lymphoma Potential, Medicine +7

A novel MDMA analogue, UWA‐101, that lacks psychoactivity and cytotoxicity, enhances <scp>l</scp> ‐DOPA benefit in parkinsonian primates

Tom H. Johnston, Zak A. Millar, Philippe Huot et al. · The FASEB Journal · 2012 · 26 citations

Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

Michael Gandy, Matthew J. McIldowie, Katie D. Lewis et al. · MedChemComm · 2010 · 14 citations